Beverly Drucker, MD, PhD
DownloadHi-Res Photo
Cards
Appointments
Medical Oncology
Primary
Contact Info
About
Titles
Assistant Professor of Medicine (Medical Oncology)
Appointments
Medical Oncology
Assistant ProfessorPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology
- Subset Medical Oncology Faculty
- Yale Cancer Center
- Yale Medicine
Education & Training
- MD
- Columbia University College of Physician & Surgeons
- PhD
- Columbia University School of Graduate Arts and Sciences, Molecular Biology (1993)
- MS
- Yale University, Molecular Biophysics & Biochemistry (1985)
- BS
- Yale University, Molecular Biophysics & Biochemistry (1985)
Research
Research at a Glance
Publications Timeline
A big-picture view of Beverly Drucker's research output by year.
7Publications
412Citations
Publications
2009
Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study
Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study. Clinical Genitourinary Cancer 2009, 7: e58-e65. PMID: 19815483, DOI: 10.3816/cgc.2009.n.025.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRenal cell carcinomaMulticenter phase I/II studyPhase I/II studyStage IV renal cell carcinomaPF-3512676II studyCell carcinomaAntitumor activityAdvanced metastatic renal cell carcinomaToll-like receptor 9 agonistMetastatic renal cell carcinomaAdvanced renal cell carcinomaLocal injection site reactionsPhase IGrade 3 fatigueGrade 4 AEsModest antitumor activityObjective response rateDose-limiting toxicityFlu-like symptomsInjection site reactionsReceptor 9 agonistSingle-agent treatmentPhase II expansionOpen label
2005
Renal cell carcinoma: Current status and future prospects
Drucker BJ. Renal cell carcinoma: Current status and future prospects. Cancer Treatment Reviews 2005, 31: 536-545. PMID: 16236454, DOI: 10.1016/j.ctrv.2005.07.009.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAdvanced renal cell carcinomaRenal cell carcinomaTotal nephrectomyLocalized Renal Cell CarcinomaStandard systemic treatmentSubset of patientsMost patientsSystemic treatmentCurative treatmentRadical nephrectomyPoor prognosisCell carcinomaUnderlying pathophysiologyStandard treatmentRenal tumorsInvasive treatmentNew agentsTumor growthNephrectomyPatientsEarly detectionMolecular pathwaysSurgeryTreatmentDiagnostic methodsBladder cancer. Clinical practice guidelines in oncology.
Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2005, 3: 4-5, 19-34. PMID: 19813320.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsUrothelial tumorsCombined-modality approachIndividual patient's likelihoodClinical practice guidelinesStage of diseaseSpectrum of diseaseRange of prognosesCategories of diseaseUrothelial tractExtensive diseaseMetastatic diseaseStandard therapyMost recurrencesNew lesionsPatient's likelihoodOrgan preservationImproved outcomesMolecular stagingPractice guidelinesSurgical proceduresRadiation therapyGuide managementNew agentsAdvanced stageNew treatments
2004
Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma
Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M, Motzer RJ. Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma. Journal Of Clinical Oncology 2004, 22: 3720-3725. PMID: 15365068, DOI: 10.1200/jco.2004.10.155.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic renal cell carcinomaRenal cell carcinomaGrade 3 sensory neuropathyPartial responseSensory neuropathyCell carcinomaM2 groupAdvanced renal cell carcinomaToxicity of bortezomibPhase II trialAssessable patientsStable diseaseII trialInterferon alfaUnacceptable toxicityClinical responseCytokine therapyCombination therapyIntravenous administrationNovel agentsIndividual patientsDose reductionResponse durationHigh doseAntitumor effects
2003
Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma
Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, Motzer R. Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma. Investigational New Drugs 2003, 21: 341-345. PMID: 14578682, DOI: 10.1023/a:1025472712456.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsRenal cell carcinomaAdvanced renal cell carcinomaPhase II trialII trialCell carcinomaMemorial Sloan Kettering Cancer Center databaseMetastatic renal cell carcinomaCancer Center databaseProgression of diseaseMonths of startEvaluable patientsMedian TTPPartial responseCell patientsDisease progressionPatientsTreatment efficacyCenter databaseZD1839Antitumor activityProgressionTrialsMonthsFurther studiesCarcinomaPrognostic Factors for Metastatic Kidney Cancer
Drucker BJ, Mazumdar M, Motzer RJ. Prognostic Factors for Metastatic Kidney Cancer. Cancer Treatment And Research 2003, 116: 139-153. PMID: 14650830, DOI: 10.1007/978-1-4615-0451-1_8.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsResponse rateMetastatic renal cell carcinomaStudy of immunotherapyEffective systemic therapyMetastatic kidney cancerStandard cytotoxic chemotherapyRenal cell cancerSpontaneous tumor regressionRenal cell carcinomaSignificant antitumor effectHormonal therapyUntreated patientsCytotoxic chemotherapyHormone therapyMetastatic RCCSystemic therapyPrognostic factorsCell cancerLymphocytic infiltrationPoor prognosisCell carcinomaRenal tumorsTumor regressionKidney cancerAntitumor effects
2002
Prognostic factors for biologic therapy in kidney cancer
Drucker BJ. Prognostic factors for biologic therapy in kidney cancer. Current Urology Reports 2002, 3: 31-36. PMID: 12084217, DOI: 10.1007/s11934-002-0008-5.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPrior nephrectomyCytokine therapyPrognostic factorsGood performance statusNormal lactate dehydrogenaseMajority of patientsLevels of cytokinesPresence of eosinophilsRenal cell cancerSubpopulations of lymphocytesLack of anemiaBiologic therapyPerformance statusImproved survivalCell cancerDisease characteristicsTumor responseNormal calciumImmune parametersInterleukin-2Kidney cancerTherapeutic benefitResponse rateTherapyLactate dehydrogenase
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date02/01/2023Recruiting ParticipantsA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
HIC ID2000026850RoleSub InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsParallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsA Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
HIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting Participants
Clinical Care
Fact Sheets
Hormonal Therapy for Cancer
Learn More on Yale MedicinePeritoneal Cancer
Learn More on Yale MedicineInflammatory Breast Cancer
Learn More on Yale MedicineGerm Cell Tumors
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- May 01, 2023
Connecticut Magazine’s 2023 “Top Doctors” issue recognizes 81 Smilow Cancer Hospital and Yale Cancer Center physicians
- February 02, 2023
Smilow Breast Cancer Care Referrals in Greenwich and Stamford
- September 01, 2022Source: Health Extensions
Specialized Team Tackles Gynecologic Cancers
- May 03, 2022
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as Connecticut Magazine 'Best Doctors'
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Administrative Support